Aptamer Group and PinotBio collaborate to develop new therapeutic drug conjugates
Back

02nd June 2021

Aptamer Group and PinotBio collaborate to develop new therapeutic drug conjugates

Aptamer Group Limited, the developer of Optimer™ Therapeutics, and PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, today announces that they have entered into a strategic collaboration agreement. The agreement is to develop Optimer-drug conjugates for targeted drug delivery combining Aptamer Group’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker.

 

Optimer therapeutics are optimized aptamer solutions. Optimer-drug conjugates offer uniquely specific targeting vehicles for the delivery of therapeutic agents to selected cell populations and tissues for the treatment of disease.

For the full story, please visit the Aptamer Group website.